Nuwellis, Inc. To Report Fourth Quarter and Full Year 2023 Financial Results on March 5, 2024
February 27 2024 - 8:00AM
Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused
on transforming the lives of people with fluid overload, today
announced that it will release financial results for the fourth
quarter and full year of 2023 on Tuesday, March 5, 2024. Nuwellis
will host a conference call and webcast at 9:00 AM ET to discuss
its financial results and provide a general business update.
To access the live webcast, please visit the
Investors page of the Nuwellis website at https://ir.nuwellis.com.
Alternatively, you may access the live conference call by dialing
1-833-816-1404 (U.S) or 1-412-317-0497 (international) and using
the conference ID: 10185035. An audio archive of the webcast will
be available following the call on the Investors page at
https://ir.nuwellis.com.
About Nuwellis
Nuwellis, Inc. (Nasdaq: NUWE) is a medical
technology company dedicated to transforming the lives of patients
suffering from fluid overload through science, collaboration, and
innovation. The company is focused on commercializing the Aquadex
SmartFlow® system for ultrafiltration therapy. Nuwellis is
headquartered in Minneapolis, with a wholly owned subsidiary in
Ireland. For more information visit ir.nuwellis.com or visit us on
LinkedIn or X.
About the Aquadex SmartFlow®
System
The Aquadex SmartFlow system delivers clinically
proven therapy using a simple, flexible and smart method of
removing excess fluid from patients suffering from hypervolemia
(fluid overload). The Aquadex SmartFlow system is indicated for
temporary (up to 8 hours) or extended (longer than 8 hours in
patients who require hospitalization) use in adult and pediatric
patients weighing 20 kg or more whose fluid overload is
unresponsive to medical management, including diuretics. All
treatments must be administered by a health care provider, within
an outpatient or inpatient clinical setting, under physician
prescription, both having received training in extracorporeal
therapies.
CONTACTS
INVESTORS:
Vivian CervantesGilmartin Group LLC ir@nuwellis.com
Newellis (NASDAQ:NUWE)
Historical Stock Chart
From Aug 2024 to Sep 2024
Newellis (NASDAQ:NUWE)
Historical Stock Chart
From Sep 2023 to Sep 2024